Cellulitis‐like Sweet Syndrome caused by adalimumab therapy for severe hidradenitis suppurativa

2020 ◽  
Vol 61 (4) ◽  
Author(s):  
Elena Canal Garcia ◽  
Johanna del Pilar Vargas Ramos ◽  
Rafael Aguayo Ortiz
Keyword(s):  
Hidradenitis Suppurativa ◽  
Sweet Syndrome ◽  
Adalimumab Therapy

Seven Years-Experience of adalimumab therapy for hidradenitis suppurativa in a real-life dermatologic setting

2021 ◽  
pp. 1-10
Author(s):  
G. Odorici ◽  
L. Pacetti ◽  
R. Forconi ◽  
N. Schettini ◽  
P. Zedde ◽  
...  
Keyword(s):  
Hidradenitis Suppurativa ◽  
Real Life ◽  
Adalimumab Therapy

scholarly journals Long-term Successful Adalimumab Therapy in Severe Hidradenitis Suppurativa

2009 ◽  
Vol 145 (5) ◽  
Author(s):  
Ricardo Blanco ◽  
Víctor M. Martínez-Taboada ◽  
Ignacio Villa ◽  
M. Carmen González-Vela ◽  
Héctor Fernández-Llaca ◽  
...  
Keyword(s):  
Hidradenitis Suppurativa ◽  
Adalimumab Therapy

scholarly journals Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series

2019 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Ching-Chi Chi ◽  
Chi-Feng Yen ◽  
Yu-Huei Huang
Keyword(s):  
Hidradenitis Suppurativa ◽  
Case Series ◽  
Adalimumab Therapy

scholarly journals The Impact of the Covid-19 Pandemic with Hidradenitis suppurativa Being Treated with Adalimumab: Evidence from Real-World Data

2020 ◽  
Vol 5 (4) ◽  
Author(s):  
Turkmen M
Keyword(s):  
Real World ◽  
Hidradenitis Suppurativa ◽  
Real World Data ◽  
Observational Analysis ◽  
World Data ◽  
Related Disease ◽  
Number Of Patients ◽  
Adalimumab Therapy ◽  
Study Population ◽  
The Impact

Background: There is uncertainty concerning the outcome of coronavirus disease-19 (COVID-19) infections in patients who are receiving adalimumab for hidradenitis suppurativa (HS) treatment. Objectives: This study aims to investigate the effect of adalimumab in HS patients during COVID 19 outbreak. Methods: We performed a retrospective observational analysis of the moderate-to-severe HS patients under adalimumab therapy, with reporting the number of patients hospitalized or who died from COVID 19 infection between 13 March 2020 and 31 July 2020. Results: Eighty nine patients who continued their therapy during pandemic were evaluated retrospectively. There were no cases of death from COVID-related disease in our study population or patients hospitalized for COVID-related disease. Conclusions: We suggest continuing the treatment of ADA in HS patients, under COVID-19 pandemic.

Malignancy and infection risk during adalimumab therapy in hidradenitis suppurativa

2020 ◽  
Vol 45 (7) ◽  
pp. 859-865 ◽  
Author(s):  
J. W. Frew ◽  
C. S. Jiang ◽  
N. Singh ◽  
D. Grand ◽  
K. Navrazhina ◽  
...  
Keyword(s):  
Hidradenitis Suppurativa ◽  
Infection Risk ◽  
Adalimumab Therapy

scholarly journals Sweet syndrome in a patient with Hidradenitis Suppurativa

2020 ◽  
Vol 8 (4) ◽  
pp. 772-773
Author(s):  
Lakshay Jain ◽  
Sreenath Meegada
Keyword(s):  
Hidradenitis Suppurativa ◽  
Sweet Syndrome
Sign in / Sign up

Export Citation Format

Share Document